Summary
Menogaril, a new semisynthetic anthracycline antibiotic, was administered to 35 patients with advanced colorectal cancer. The drug was infused over 2 hr at a dose of 160 mg/sqm or 200 mg/sqm repeated every 4 weeks. Twenty-seven patients were evaluable for response and no objective responses were achieved. Myelosuppression, only leukopenia, was usually of mild-moderate degree and occurred in 63% of the patients. Twenty-seven percent of the patients experienced severe leukopenia. Local erythema and phlebitis were frequently observed and were severe in 13% of the patients. Nausea/vomiting (66%) and alopecia (50%) were of mild-moderate degree.
This study suggests that menogaril at these doses and schedule had no activity in advanced colorectal cancer.
Similar content being viewed by others
References
Bhuyan BK, Neil GL, Li LH, McGovren JP, Wiley PF: Chemistry and biological activity of 7-con-O-methylnogaril (7-con-OMEN). In: ST Crooke, SD Reich (eds) Anthracyclines: Current Status and New Developments. Academic Press, New York 1980, pp 365–395
McGovren JP, Nelson KG, Lassus M, Cradock JC, Plowman J, Christopher JP: Menogaril: a new anthracycline agent entering clinical trials. Invest New Drugs 2:359–367, 1984
Dodion P, Sanders C, Rombaut W, Rozencweig M, Kitt MM, Kenis Y, Klastersky J: Activity of menogaril and N-demethylmenogaril in a human tumor cloning assay. Eur J Cancer Clin Oncol 22:245–249, 1986
Dodion P, Sessa C, Joss R, Crespeigne N, Willems Y, Kitt M, Abrams J, Finet C, Brewer JE, Adams WJ, Earhart RH, Rozencweig M, Kenis Y, Cavalli F: Phase I study of intravenous menogaril administered intermittently. J Clin Oncol 4:767–774, 1986
Dorr FA, Von Hoff DD, Kuhn JG, Schwartz R, Kisner DL: Phase I clinical investigation of 7-con-O-methylnogaril, a new anthracycline antibiotic. Cancer Res 46:2562–2565, 1986
Sigman LM, Van Echo DA, Egorin MJ, Whitacre MY, Aisner J: Phase I trial of menogaril administered as an intermittent daily infusion for 5 days. Cancer Treat Rep 70:721–725, 1986
Author information
Authors and Affiliations
Additional information
for the EORTC Early Clinical Trials Group (EORTC/ECTG)
Rights and permissions
About this article
Cite this article
Holdener, E.E., ten Bokkel Huinink, W.W., Decoster, G. et al. Phase II trial of menogaril in advanced colorectal cancer. Invest New Drugs 6, 227–230 (1988). https://doi.org/10.1007/BF00175404
Issue Date:
DOI: https://doi.org/10.1007/BF00175404